- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Velcade Approved for Mantle Cell Lymphoma in Europe
The drug has been approved for treatment-naive patients who are ineligible for transplant.
European regulators have expanded the label on Johnson & Johnson’s multiple myeloma drug Velcade to cover mantle cell lymphoma.
Specifically, the European Commission has approved a variation to the terms of J&J unit Janssen’s marketing authorisation of Velcade (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for adults with previously-untreated MCL who are unsuitable for blood stem-cell transplantation. The drug is currently indicated in Europe for multiple myeloma, either as monotherapy or in combinations.
Thomas Stark, head of medical affairs at Janssen Europe, Middle East and Africa, noted that “we already offer Imbruvica (ibrutinib) as a second-line treatment in MCL and are pleased to be able to provide additional treatment options for this disease”. Velcade is already approved for MCL in the USA, marketed by Takeda’s Millennium unit.
Complete report on PharmacyTimes: http://bit.ly/16Kaawc
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
